Headlines Expert Newsletters Covid-19 Specialties Trending Feeds Videos

Oncology Nursing News

Patients with progressed multiple myeloma experienced deep and durble responses through CAR T-cell therapy ciltacabtagene autoleucel

  • A single cilta-cel infusion was administered to 20 patients 5 to 7 days after the start of lymphodepletion. With a median follow-up of 5.8 months at data cutoff, ORR was 95%, including 75% of patients who achieved a complete response (CR) or better. https://t.co/UAMU5oGkU5 - view on twitter